Abstract
Drug abuse is currently a large economic and societal burden in countries around the globe. Many drugs of abuse currently lack adequate therapies aimed at treating both the addiction and negative complications often associated with their use. Sigma-1 receptors were discovered over 30 years ago and have recently become targets for the development of pharmacotherapies aimed at treating substance abuse and addiction. In vivo preclinical studies have revealed that sigma receptor ligands are able to ameliorate select behavioral effects of many drugs of abuse including cocaine, methamphetamine, ethanol and nicotine. In addition, recent studies have begun to elucidate the mechanisms by which sigma-1 receptors modulate the effects of these drugs on neurotransmission, gene regulation and neuroplasticity. Overall, these recent findings suggest that compounds targeting sigma-1 receptors may represent a potential new class of therapeutics aimed at treating drug abuse. Future studies involving clinical populations will be critical for validating the therapeutic potential of sigma-1 receptor ligands for the treatment of substance abuse.
Keywords: Sigma receptor, cocaine, methamphetamine, nicotine, ethanol, drug abuse, addiction, opioid, neurotransmission, neuroplasticity
Current Pharmaceutical Design
Title: Sigma-1 Receptors: Potential Targets for the Treatment of Substance Abuse
Volume: 18 Issue: 7
Author(s): Matthew J. Robson, Bahar Noorbakhsh, Michael J. Seminerio and Rae R. Matsumoto
Affiliation:
Keywords: Sigma receptor, cocaine, methamphetamine, nicotine, ethanol, drug abuse, addiction, opioid, neurotransmission, neuroplasticity
Abstract: Drug abuse is currently a large economic and societal burden in countries around the globe. Many drugs of abuse currently lack adequate therapies aimed at treating both the addiction and negative complications often associated with their use. Sigma-1 receptors were discovered over 30 years ago and have recently become targets for the development of pharmacotherapies aimed at treating substance abuse and addiction. In vivo preclinical studies have revealed that sigma receptor ligands are able to ameliorate select behavioral effects of many drugs of abuse including cocaine, methamphetamine, ethanol and nicotine. In addition, recent studies have begun to elucidate the mechanisms by which sigma-1 receptors modulate the effects of these drugs on neurotransmission, gene regulation and neuroplasticity. Overall, these recent findings suggest that compounds targeting sigma-1 receptors may represent a potential new class of therapeutics aimed at treating drug abuse. Future studies involving clinical populations will be critical for validating the therapeutic potential of sigma-1 receptor ligands for the treatment of substance abuse.
Export Options
About this article
Cite this article as:
J. Robson Matthew, Noorbakhsh Bahar, J. Seminerio Michael and R. Matsumoto Rae, Sigma-1 Receptors: Potential Targets for the Treatment of Substance Abuse, Current Pharmaceutical Design 2012; 18 (7) . https://dx.doi.org/10.2174/138161212799436601
DOI https://dx.doi.org/10.2174/138161212799436601 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
LncRNA SNHG7 Serves as a Potential Biomarker on the Prognosis of Human Solid Tumors: A Meta-Analysis
Current Pharmaceutical Biotechnology Rheumatoid Arthritis: A Clinical Overview of New Diagnostic and Treatment Approaches
Current Topics in Medicinal Chemistry Basilar Apex Aneurysms in the Setting of Carotid Artery Stenosis: Case Series and Angiographic Anatomic Study
Current Neurovascular Research Editorial [Hot Topic: The Eye in Rheumatological Disease (Guest Editors: Sue Lightman and Simon Taylor)]
Current Rheumatology Reviews Neurotuberculosis: An Overview
Central Nervous System Agents in Medicinal Chemistry Update on Intravenous Immunoglobulins (IVIg) Mechanisms of Action and Off- Label use in Autoimmune Diseases
Current Pharmaceutical Design Ginger and Heart Health: From Mechanisms to Therapeutics
Current Molecular Pharmacology Pentoxifylline Use in Dermatology
Inflammation & Allergy - Drug Targets (Discontinued) ATP Binding Cassette Transporter A1 (ABCA1) Associated Proteins:Potential Drug Targets in the Metabolic Syndrome and Atherosclerotic Disease?
Current Pharmaceutical Biotechnology SANTAVAC ™: A Novel Universal Antigen Composition for Developing Cancer Vaccines
Recent Patents on Biotechnology Recurrent Pregnancy Losses
Current Women`s Health Reviews Nitric Oxide is a Central Common Metabolite in Vascular Dysfunction Associated with Diseases of Human Pregnancy
Current Vascular Pharmacology Skin Prick Test with Self-Saliva in Patients with Oral Aphthoses: A New Diagnostic Pathergy for Behcets Disease and Recurrent Aphthosis
Inflammation & Allergy - Drug Targets (Discontinued) Will Antirheumatic Treatment Improve Cardiovascular Outcomes in Patients with Rheumatoid Arthritis?
Current Pharmaceutical Design Refractory Behçet’s Disease with Multi-organ Involvement - Learning from Failure
Current Rheumatology Reviews Adrenal Hyperandrogenism and Polycystic Ovary Syndrome
Current Pharmaceutical Design Anti-Inflammatory Effects of Triterpenoids; Naturally Occurring and Synthetic Agents
Mini-Reviews in Organic Chemistry The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy
Current Drug Targets Cerebral Amyloid Angiopathy-related Intracerebral Hemorrhage Score For Predicting Outcome
Current Neurovascular Research Opioid-induced Cardioprotection
Current Pharmaceutical Design